Table 1 Clinico-pathologic characteristics and DDRG mutation status of 531 patients with prostate cancer stratified by ancestry.

Gleason Grade

0.166

 3 + 3

127 (51.6%)

160 (59.9%)

 3 + 4

69 (28.0%)

63 (23.6%)

 4 + 3/8-10

50 (20.3%)

44 (16.5%)

Missing Data

13

5

Diagnosis Age (in years)

0.078

 Old (>55 years)

193 (74.5%)

220 (80.9%)

 Young (≤55 years)

66 (25.5%)

52 (19.1%)

PSA Category (ng/ml)

0.241

 (<4)

59 (23.0%)

81 (29.8%)

 (4–9)

164 (63.8%)

165 (60.7%)

 (10–20)

26 (10.1%)

19 (7.0%)

 (>20)

8 (3.1%)

7 (2.6%)

Missing Data

2

0

Pathological T Stage

0.041

 T1a–T2a

6 (2.6%)

17 (6.7%)

 T2b–T2c

166 (72.2%) 158

158 (62.2%)

 T3a–T3c

58 (25.2%)

78 (30.7%)

 T4

0 (0.0%)

2 (0.8%)

Missing Data

29

18

 BCR

0.788

 No

203 (86.0%)

224 (85.2%)

 Yes

33 (14.0%)

39 (14.8%)

Missing Data

23

9

Metastasis

0.451

 No

250 (96.5%)

259 (95.2%)

 Yes

9 (3.5%)

13 (4.8%)

Any DDRG Mutations

0.687

No Mutation

200 (77.2%)

206 (75.7%)

Any Mutation

59 (22.8%)

66 (24.3%)

Number of DDRG Mutations Per Patient

0.170

 0

200 (77.2%)

206 (75.7%)

 1

56 (21.6%)

56 (20.6%)

 2

3 (1.2%)

10 (3.7%)